Patents by Inventor Yong Qian

Yong Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020007075
    Abstract: This invention relates to novel ureas or carbamates of N-heterocyclic carboxylic acids and carboxylic acid isosteres, their preparation and use for treating neurological disorders including physically damaged nerves and neurodegenerative diseases, and for treating alopecia and promoting hair growth.
    Type: Application
    Filed: January 30, 2001
    Publication date: January 17, 2002
    Inventors: Gregory S. Hamilton, Mark H. Norman, Yong-Qian Wu
  • Patent number: 6331537
    Abstract: This invention relates to novel N-heteorocyclic carboxylic acids and carboxylic acid isosteres, their preparation and use for treating neurological disorders including physically damaged nerves and neurodengenerative diseases, for treating alopecia and promoting hair growth, for treating vision disorders and/or improving vision, and for treating memory impairment and/or enhancing memory performance by administering such compounds.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: December 18, 2001
    Assignee: GPI Nil Holdings, Inc.
    Inventors: Gregory S. Hamilton, Mark H. Norman, Yong-Qian Wu
  • Patent number: 5981507
    Abstract: Novel compositions of nucleotide analog prodrugs for the treatment of viral infections and cancer are herein disclosed. The prodrugs have a biocompatible polymeric carrier conjugated to the nucleotide analog via an amino-phosphate linkage. The amino group is provided by the carrier, which either inherently possesses a primary amine, or is modified with reactive groups that incorporate the primary amine onto the carrier. The carrier can be a polyamino acid, a polyvinylic polymer, a polysaccharide or combinations thereof, such as polylysine, HPMA, dextran, hydroxyethyl starch, or polyethylene glycol; the nucleotide analog can be ribavirin araA, AZT, acyclovir, 5-FUDR, araC or ddI. Methods of treating a viral infection of cancer using these prodrugs are also disclosed. The prodrugs endow the nucleotide analogs with substantially enhanced therapeutic efficacy and reduces toxicity in comparison to the nucleotide analog alone.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: November 9, 1999
    Assignee: Advanced Magnetics, Inc.
    Inventors: Lee Josephson, Ernest V. Groman, Yong-Qian Wu